European Journal of Cancer
Volume 39, Issue 9 , Pages 1318-1329 , June 2003

Trail-induced apoptosis and interaction with cytotoxic agents in soft tissue sarcoma cell lines

  • S Tomek

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +43-1-40400-4445; fax: +43-1-40400-4452
    • ,
  • W Koestler

      Affiliations

    • Clinical Division of Oncology, Department of Medicine I, Waehringer Guertel 18-20, A-1090 Vienna, Austria
    • ,
  • P Horak

      Affiliations

    • Clinical Division of Oncology, Department of Medicine I, Waehringer Guertel 18-20, A-1090 Vienna, Austria
    • ,
  • T Grunt

      Affiliations

    • Clinical Division of Oncology, Department of Medicine I, Waehringer Guertel 18-20, A-1090 Vienna, Austria
    • ,
  • T Brodowicz

      Affiliations

    • Clinical Division of Oncology, Department of Medicine I, Waehringer Guertel 18-20, A-1090 Vienna, Austria
    • ,
  • I Pribill

      Affiliations

    • Clinical Division of Oncology, Department of Medicine I, Waehringer Guertel 18-20, A-1090 Vienna, Austria
    • ,
  • J Halaschek

      Affiliations

    • Clinical Division of Oncology, Department of Medicine I, Waehringer Guertel 18-20, A-1090 Vienna, Austria
    • ,
  • G Haller

      Affiliations

    • Clinical Division of Oncology, Department of Medicine I, Waehringer Guertel 18-20, A-1090 Vienna, Austria
    • ,
  • C Wiltschke

      Affiliations

    • Clinical Division of Oncology, Department of Medicine I, Waehringer Guertel 18-20, A-1090 Vienna, Austria
    • ,
  • C.C Zielinski

      Affiliations

    • Clinical Division of Oncology, Department of Medicine I, Waehringer Guertel 18-20, A-1090 Vienna, Austria
    • Ludwig Boltzmann Institute for Clinical Experimental Oncology, Vienna University Hospital, Waehringer Guertel 18-20, A-1090 Vienna, Austria
    • ,
  • M Krainer

      Affiliations

    • Clinical Division of Oncology, Department of Medicine I, Waehringer Guertel 18-20, A-1090 Vienna, Austria

Received 23 September 2002 ,Revised 10 February 2003 ,Accepted 27 February 2003.

References 

  1. Antman K, Crowley J, Balcerzak SP, et al.  An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J. Clin. Oncol. 1993;11:1276–1285
  2. Borden EC, Amato DA, Edmonson JH, Ritch PS, Shiraki M. Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas. Cancer. 1990;66:862–867
  3. Brodowicz T, Wiltschke C, Kandioler-Eckersberger D, et al.  Inhibition of proliferation and induction of apoptosis in soft tissue sarcoma cells by interferon-alpha and retinoids. Br. J. Cancer. 1999;80:1350–1358
  4. Tomazic VJ, Farha M, Loftus A, Elias EG. Anti-tumor activity of recombinant tumor necrosis factor on mouse fibrosarcoma in vivo and in vitro. J. Immunol. 1988;140:4056–4061
  5. Meager A. A cytotoxicity assay for tumour necrosis factor using a human rhabdomyosarcoma cell line. J. Immunol. Methods. 1991;144:141–143
  6. Schulze-Osthoff K, Bakker AC, Vanhaesebroeck B, Beyaert R, Jacob WA, Fiers W. Cytotoxic activity of tumor necrosis factor is mediated by early damage of mitochondrial functions. Evidence for the involvement of mitochondrial radical generation. J. Biol. Chem. 1992;267:5317–5323
  7. Claudio E, Segade F, Wrobel K, Ramos S, Bravo R, Lazo PS. Molecular mechanisms of TNFalpha cytotoxicity (activation of NF-kappaB and nuclear translocation). Exp. Cell Res. 1996;224:63–71
  8. Nagata S. Apoptosis by death factor. Cell. 1997;88:355–365
  9. Tartaglia LA, Goeddel DV. Two TNF receptors. Immunol Today. 1992;13:151–153
  10. Eggermont AM, Schraffordt Koops H, Klausner JM, et al.  Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann. Surg. 1996;224:756–764 (discussion 64-5.)
  11. Eggermont AM, Schraffordt Koops H, Lienard D, et al.  Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas (a multicenter trial). J. Clin. Oncol. 1996;14:2653–2665
  12. Eggermont AM, Schraffordt Koops H, Klausner JM, et al.  Isolated limb perfusion with high-dose tumor necrosis factor-alpha for locally advanced extremity soft tissue sarcomas. Cancer Treat Res. 1997;91:189–203
  13. Gutman M, Inbar M, Lev-Shlush D, et al.  High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation. Cancer. 1997;79:129–137
  14. Katsen AD, Vollmar B, Mestres-Ventura P, Menger MD. Cell surface and nuclear changes during TNF-alpha-induced apoptosis in WEHI 164 murine fibrosarcoma cells. A correlative light, scanning, and transmission electron microscopical study. Virchows Arch. 1998;433:75–83
  15. Lev-Chelouche D, Abu-Abeid S, Kollander Y, et al.  Multifocal soft tissue sarcoma (limb salvage following hyperthermic isolated limb perfusion with high-dose tumor necrosis factor and melphalan). J. Surg. Oncol. 1999;70:185–189
  16. Ten Hagen TL, Van Der Veen AH, Nooijen PT, Van Tiel ST, Seynhaeve AL, Eggermont AM. Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats. Int. J. Cancer. 2000;87:829–837
  17. van Der Veen AH, ten Hagen TL, de Wilt JH, van Ijken MG, Eggermont AM. An overview on the use of TNF-alpha (our experience with regional administration and developments towards new opportunities for systemic application). Anticancer Res. 2000;20(5B):3467–3474
  18. Wiley SR, Schooley K, Smolak PJ, et al.  Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995;3:673–682
  19. Marsters SA, Pitti RM, Donahue CJ, Ruppert S, Bauer KD, Ashkenazi A. Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. Curr. Biol. 1996;6:750–752
  20. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 1996;271:12687–12690
  21. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res. 1999;59:734–741
  22. Tanaka S, Sugimachi K, Shirabe K, Shimada M, Wands JR. Expression and antitumor effects of TRAIL in human cholangiocarcinoma. Hepatology. 2000;32:523–527
  23. Ozawa F, Friess H, Kleeff J, et al.  Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer. Cancer Lett. 2001;163:71–81
  24. Petak I, Douglas L, Tillman DM, Vernes R, Houghton JA. Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis. Clin. Cancer Res. 2000;6:4119–4127
  25. Van Valen F, Fulda S, Truckenbrod B, et al.  Apoptotic responsiveness of the Ewing's sarcoma family of tumours to tumour necrosis factor-related apoptosis-inducing ligand (TRAIL). Int. J. Cancer. 2000;88:252–259
  26. Wu M, Das A, Tan Y, Zhu C, Cui T, Wong MC. Induction of apoptosis in glioma cell lines by TRAIL/Apo-2l. J. Neurosci. Res. 2000;61:464–470
  27. Yamanaka T, Shiraki K, Sugimoto K, et al.  Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines. Hepatology. 2000;32:482–490
  28. Walczak H, Miller RE, Ariail K, et al.  Tumoricidal activity of tumor necrosis factor-related apoptosis- inducing ligand in vivo. Nat. Med. 1999;5:157–163
  29. Ashkenazi A, Pai RC, Fong S, et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 1999;104:155–162
  30. Pan G, O'Rourke K, Chinnaiyan AM, et al.  The receptor for the cytotoxic ligand TRAIL. Science. 1997;276:111–113
  31. Wu GS, Burns TF, McDonald ER, et al.  Induction of the TRAIL receptor KILLER/DR5 in p53-dependent apoptosis but not growth arrest. Oncogene. 1999;18:6411–6418
  32. Wu GS, Burns TF, McDonald ER, et al.  KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat. Genet. 1997;17:141–143
  33. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science. 1997;277:815–818
  34. Walczak H, Degli-Esposti MA, Johnson RS, et al.  TRAIL-R2 (a novel apoptosis-mediating receptor for TRAIL). Embo J. 1997;16:5386–5397
  35. Screaton GR, Mongkolsapaya J, Xu XN, Cowper AE, McMichael AJ, Bell JI. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr. Biol. 1997;7:693–696
  36. Sheridan JP, Marsters SA, Pitti RM, et al.  Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 1997;277:818–821
  37. Degli-Esposti MA, Smolak PJ, Walczak H, et al.  Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J. Exp. Med. 1997;186:1165–1170
  38. Pan G, Ni J, Yu G, Wei YF, Dixit VM. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling. FEBS Lett. 1998;424:41–45
  39. Marsters SA, Sheridan JP, Pitti RM, et al.  A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr. Biol. 1997;7:1003–1006
  40. Schneider P, Thome M, Burns K, et al.  TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity. 1997;7:831–836
  41. Kim K, Fisher MJ, Xu SQ, el-Deiry WS. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin. Cancer Res. 2000;6:335–346
  42. Dejosez M, Ramp U, Mahotka C, et al.  Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan. Cell Death Differ. 2000;7:1127–1136
  43. Ahmad M, Shi Y. TRAIL-induced apoptosis of thyroid cancer cells (potential for therapeutic intervention). Oncogene. 2000;19:3363–3371
  44. Zhang XD, Nguyen T, Thomas WD, Sanders JE, Hersey P. Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett. 2000;482:193–199
  45. Emery JG, McDonnell P, Burke MB, et al.  Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 1998;273:14363–14367
  46. Keane MM, Ettenberg SA, Lowrey GA, Russell EK, Lipkowitz S. Fas expression and function in normal and malignant breast cell lines. Cancer Res. 1996;56:4791–4798
  47. Chou TC, Talalay P. Analysis of combined drug effects (a new look at a very old problem). Trends Pharmacol. Sci. 1983;4:450–454
  48. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships (the combined effects of multiple drugs or enzyme inhibitors). Adv. Enzyme Regul. 1984;22:27–55
  49. Sacks PG, Harris D, Chou TC. Modulation of growth and proliferation in squamous cell carcinoma by retinoic acid (a rationale for combination therapy with chemotherapeutic agents). Int. J. Cancer. 1995;61:409–415
  50. Grunt TW. Tyrphostins and retinoids cooperate during inhibition of in vitro growth of ovarian cancer cells. Cancer Lett. 2003;189:147–156
  51. Peter ME. The trail discussion (it is FADD and caspase-8!). Cell Death Differ. 2000;7:759–760
  52. Ogasawara J, Watanabe-Fukunaga R, Adachi M, et al.  Lethal effect of the anti-Fas antibody in mice. Nature. 1993;364:806–809
  53. Brodowicz T, Kostler WJ, Wiltschke C, Zielinski CC. Efficacy of docetaxel in the second-line treatment of locally advanced or metastatic soft tissue sarcoma after failure of chemotherapy with anthracycline or ifosfamide. Am. J. Clin. Oncol. 1999;22:535
  54. Verweij J, Lee SM, Ruka W, et al.  Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults (a study of the European organization for research and treatment of cancer soft tissue and bone sarcoma group). J. Clin. Oncol. 2000;18:2081–2086
  55. Kostler WJ, Brodowicz T, Attems Y, et al.  Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma (results of a phase II trial). Ann. Oncol. 2001;12:1281–1288

PII: S0959-8049(03)00227-2

doi: 10.1016/S0959-8049(03)00227-2

European Journal of Cancer
Volume 39, Issue 9 , Pages 1318-1329 , June 2003

Article Tools

* Image Usage & Resolution